This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Bank of America Securities Keeps Their Buy Rating on Dr. Reddy’s Laboratories Ltd. (DRREDDY)
Bank of America Securities analyst Neha Manpuria reiterated a Buy rating on Dr. Reddy’s Laboratories Ltd. yesterday and set a price target of INR1,600.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
According to TipRanks, Manpuria is a 2-star analyst with an average return of 3.4% and a 46.15% success rate.
Dr. Reddy’s Laboratories Ltd. has an analyst consensus of Hold, with a price target consensus of INR1,350.00.
Based on Dr. Reddy’s Laboratories Ltd.’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of INR88.05 billion and a net profit of INR14.37 billion. In comparison, last year the company earned a revenue of INR80.16 billion and had a net profit of INR12.55 billion
Read More on IN:DRREDDY:
Disclaimer & DisclosureReport an Issue
- Dr. Reddy’s Laboratories Receives USFDA Observations Post-Inspection
- Dr. Reddy’s Laboratories to Engage with Investors at Hyderabad Conference
- Midday Fly By: IBM to buy Confluent, Paramount goes hostile for Warner Bros.
- Immutep, Dr Reddy’s enters strategic collaboration for Eftilagimod Alfa
- Dr. Reddy’s Laboratories Releases Q2 FY26 Earnings Call Transcript
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
